Jose Halperin, M.D. is a physician and researcher at Brigham and Women’s Hospital, where he serves as Director of the Laboratory for Translational Research in the Division of Hematology, and an Associate Professor of Medicine at Harvard Medical School. He is a pioneer in the understanding of the role of the complement system and the complement regulator CD59 in the pathogenesis of diabetes complications. Dr. Halperin holds over 40 awarded or filed patents, several of which have been licensed by Harvard University to companies working on bringing his inventions to the marketplace. Previously, Dr. Halperin founded and was a board member of Best Doctors, Inc. Dr. Halperin is also a founder and board member of Bioambar, SPA.
Dr. Halperin earned his M.D. degree from the University of Buenos Aires School of Medicine.
Michael Chorev, Ph.D. is an Associate-in-Medicine at Brigham and Women’s Hospital, an Associate Professor of Medicine (Biochemistry) at the Harvard Medical School and a faculty member of the Laboratory for Translational Research at the Department of Medicine of Brigham and Women’s Hospital. He led the development of the key reagents used in the diagnosis of glycated CD59. He has co-authored over 200 scientific articles and reviews in journals, chapters in monographs and books, and over 40 awarded and filed patents. He serves as an Editor for Journal of Peptide Science and is the recipient of the 2013 Vincent du Vigneaud Award from the American Peptide Society. Prof. Chorev is co-inventor of ladostigil and rivastigmine (Exelon®). Previously, Prof. Chorev held the Drs. Margaret and Henry Zentner Professor of Pharmaceutical Chemistry Chair at Hebrew University.
Prof. Chorev received his B.Sc., M.Sc. and Ph.D. from the Hebrew University and completed his post-doctoral training at University of California, San Diego.
Christopher de Souza is a Director at Broadview Ventures in Boston and represents the fund as an Observer of the Board of Mellitus, LLC. He started his pharmaceutical career at Novartis as senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances. After Novartis, Christopher was VP of Business Development at SkyePharma US and also founded a business development consulting practice.
Dr. de Souza received an MBA from Rutgers University and a Ph.D. in physiology from Louisiana State University. He completed his post-doctoral training at “The Upjohn Company” and the Joslin Diabetes Center/Harvard Medical School.
Joyce Lonergan has over 25 years of experience in industry, venture capital and Wall Street with emerging healthcare companies. Ms. Lonergan previously served as a Managing Partner at SR One. Prior to that, Ms. Lonergan co-founded and served as Managing Director of Caxton Healthcare Venture Management, LLC. She previously served as Vice President of Corporate Development and Corporate Communications and Investor Relations at Chiron Corporation. Earlier in her career, Ms. Lonergan was a Biotechnology Equity Research Analyst at Cowen and Company. She also had previous investment and business development roles at Vector Fund Management and Repligen Corporation. Ms. Lonergan began her career in research at Tufts Medical Center.
Ms. Lonergan holds a B.S. in biology from Emmanuel College and an MBA from the Simmons College Graduate School of Management.
Bruce Phelps, Ph.D. has over 36 years of combined technical management, operational and research & development experience in biotechnology, medical devices, and diagnostics. Over the course of his career in diagnostic assay and systems development, he has been responsible for developing over 60 biomarker assays that have been implemented on manual systems, bench top analyzers, and high-throughput automated systems. Earlier in his career, he served as Chief Technology Officer of a start-up company called Aviir, was Divisional Vice President, Blood Testing at Chiron Corporation and held several technical and management positions at Abbott Laboratories.
Dr. Phelps received his B.S. in chemistry from Clarkson University and earned his Ph.D. in biochemistry from the Indiana University School of Medicine.
David Madden is a finance professional with over 30 years of experience covering all aspects of corporate finance for biotechnology, pharmaceutical, and life science companies. He has served as Chief Financial Officer for Alector, AiroMedica LLC, Vaxart, Inc., XDx, and Arriva Pharmaceuticals. Previously, he was Associate Director of Corporate Finance for Chiron Corporation, which was acquired by Novartis. Earlier in his career, he served as Director of Investment Analysis at PG&E Enterprises, Senior Associate of Business Development at National Power Company, and Development Analyst at Harbert Cogen.
Mr. Madden received his B.A. in English from the University of California, Berkeley and his MBA in finance and international business from the University of Washington Michael G. Foster School of Business. He is Board member and treasurer of Can Do Multiple Sclerosis, which delivers educational programs for those with MS and their families, and of BioScience Forum, which conducts educational activities relating to the life sciences.
Jerry Casey is a commercially focused leader with over 30 years of experience in the healthcare industry. Previously, Mr. Casey was President and Chief Operating Officer of Sekisui Diagnostics, where he was responsible for leading and directing their worldwide business. Prior to that, he spent a number of years at Genzyme Corporation running global sales and marketing for Genzyme Diagnostics. As Senior Vice President, he led the commercialization and growth of a diversified diagnostic product portfolio across the worldwide market. Earlier in his career, Mr. Casey served as Assistant Vice President of Fixed Income at Keefe, Bruyette and Woods. He began his career as a Diagnostic Sales Specialist at Abbott Laboratories.
Mr. Casey received his B.A. in political science and MBA in finance from the University of Connecticut. In addition to his work with Mellitus, he has been actively involved in several life sciences ventures, both as an advisor and an investor, while serving on multiple Boards.
Alissa Dangel, M.D. is an obstetrician and gynecologist at Tufts Medical Center and Assistant Professor at the Tufts University School of Medicine. She has been in practice for 8 years as an OB/GYN and has particular expertise in the management of gestational diabetes. Her clinical work also includes experience in the global health arena through her work as a Global Health Instructor for the Nicaragua rural health course at Tufts Medical School.
Dr. Dangel received her B.S. in environmental science from the University of Rochester and completed her M.D. at the University of Massachusetts Medical School. She completed her residency in the department of obstetrics and gynecology at the University of Maryland Medical Center. Dr. Dangel is a fellow of the American Congress of Obstetricians and Gynecologists (FACOG) and a member of the Massachusetts Medical Society. She is board certified by the American Board of Obstetrics and Gynecology.